Silexion Therapeutics Initiates Phase 2/3 Trial of SIL204 in Pancreatic Cancer

What Happened
Silexion Therapeutics Corp. announced on July 29, 2026 (via an 8-K, Item 7.01) that it has successfully initiated a Phase 2/3 clinical trial of its drug candidate SIL204 in patients with locally advanced pancreatic cancer. The company issued a press release titled “Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center,” which is furnished as Exhibit 99.1 to the filing.

Key Details

• Press release and Regulation FD disclosure filed on July 29, 2026 (Form 8-K, Item 7.01).
• Trial initiation site named: Tel Aviv Sourasky Medical Center.
• Program: SIL204 entering a combined Phase 2/3 clinical trial in locally advanced pancreatic cancer.
• The press release is included as Exhibit 99.1 to the 8-K (filing also includes cover page interactive data).

Why It Matters
Clinical trial starts are material milestones for biotech companies because they mark progression of a drug candidate through development; this move advances SIL204 toward potential efficacy and regulatory readouts that could affect Silexion’s future value. The 8-K provides factual confirmation of trial initiation but does not include clinical data, timelines for enrollment or financial details—investors should watch for subsequent updates, trial results, enrollment progress, and any partnering or funding announcements.